4-hydroxy-3-methyl-5-nitrobenzoic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-hydroxy-3-methyl-5-nitrobenzoic acid
• 英文别名: 4-Hydroxy-3-methyl-5-nitro-benzoesaeure
• 化学式: C₈H₇NO₅
• 分子量: 197.147
• InChiKey: AUQMLPTXBVNUBP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  103
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  4-羟基-3-甲基苯甲酸 在 硝酸 、 溶剂黄146 作用下， 以51.5 %的产率得到4-hydroxy-3-methyl-5-nitrobenzoic acid
  参考文献：
  名称：

  [EN] FTO INHIBITORS
  [FR] INHIBITEURS DE FTO

  摘要：

  Provided are a compound of Formula (I) as an FTO inhibitor with improved and selective FTO inhibition, a pharmaceutical composition comprising the same, and a method of inhibiting weight gain, promoting weight loss, reducing serum LDL, cholesterol, LDL-c, or triglycerides, or treating obesity or an obesity-related disease (esp. obesity-related diabetes, hyperglycemia, diabetic nephropathy, hyperlipemia, coronary heart disease, atherosclerosis, hypertension, cardiovascular or cerebrovascular disease) or Alzheimer's disease by inhibiting FTO by using the compound disclosed herein.

  公开号：

  WO2024022491A1

文献信息

• Novel bicyclic sulfonamide derivatives which are L-CPT1 inhibitors
  申请人：Ackermann Jean

  公开号：US20070191603A1

  公开（公告）日：2007-08-16

  The invention is concerned with novel heterobicyclic derivatives of formula (I) wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , V, W, X and Y are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds inhibit L-CPT1 and can be used as medicaments.

  这项发明涉及公式（I）的新异双环衍生物，其中R1、R2、R3、R4、R5、R6、V、W、X和Y的定义如描述和索赔中所述，以及其生理上可接受的盐和酯。这些化合物抑制L-CPT1，可用作药物。
• NOVEL BICYCLIC SULFONAMIDE DERIVATIVES WHICH ARE L-CPT1 INHIBITORS
  申请人：Ackermann Jean

  公开号：US20110046112A1

  公开（公告）日：2011-02-24

  The invention is concerned with novel heterobicyclic derivatives of formula (I) wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , V, W, X and Y are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds inhibit L-CPT1 and can be used as medicaments.

  本发明涉及公式（I）的新型杂环双环衍生物，其中R1、R2、R3、R4、R5、R6、V、W、X和Y如描述和权利要求中所定义，以及其生理上可接受的盐和酯。这些化合物抑制L-CPT1，可用作药物。
• Bicyclic sulfonamide derivatives which are L-CPT1 inhibitors
  申请人：Hoffmann-La Roche Inc.

  公开号：US07879845B2

  公开（公告）日：2011-02-01

  The invention is concerned with novel heterobicyclic derivatives of formula (I) wherein R1, R2, R3, R4, R5, R6, V, W, X and Y are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds inhibit L-CPT1 and can be used as medicaments.

  本发明涉及式（I）的新异杂双环衍生物，其中R1、R2、R3、R4、R5、R6、V、W、X和Y如描述和权利要求中所定义，并且其生理上可接受的盐和酯。这些化合物抑制L-CPT1并可用作药物。
• Bicyclic sulfonamide derivatives which are L-CPT 1 inhibitors
  申请人：Hoffmann-La Roche Inc.

  公开号：US08030308B2

  公开（公告）日：2011-10-04

  The invention is concerned with novel heterobicyclic derivatives of formula (I) wherein R1, R2, R3, R4, R5, R6, V, W, X and Y are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds inhibit L-CPT1 and can be used as medicaments.

  本发明涉及式（I）的新异杂双环衍生物，其中R1、R2、R3、R4、R5、R6、V、W、X和Y如描述和权利要求中所定义，以及其生理上可接受的盐和酯。这些化合物抑制L-CPT1并可用作药物。
• ACYLGUANIDINE DERIVATIVE
  申请人：Astellas Pharma Inc.

  公开号：EP2119704A1

  公开（公告）日：2009-11-18

  An object of the present invention is to provide a novel and excellent agent for treating or preventing dementia, schizophrenia and the like, based on the 5-HT5A receptor modulating action. It was confirmed that a compound characterized by a structure that a tricyclic hetero ring having a pyrrole ring at the center and guanidine are bonded via a carbonyl group has a potent 5-HT5A receptor modulating action and an excellent pharmacological action based thereon, and thus, it was found that the compound can be an excellent agent for treating or preventing dementia, schizophrenia, bipolar disorder, or attention deficit hyperactivity disorder, particularly for memory-related functional disorders such as cognitive impairments including dementia and schizophrenia, thereby completing the present invention.

  本发明的目的是提供一种基于 5-HT5A 受体调节作用的治疗或预防痴呆症、精神 分裂症等疾病的新型优良药物。经证实，一种化合物的结构特征是中心具有吡咯环的三环杂环与胍通过羰基键合，该化合物具有强效的 5-HT5A 受体调节作用和基于此的优异药理作用，因此、发现该化合物可作为治疗或预防痴呆症、精神分裂症、双相情感障碍或注意缺陷多动障碍的极佳药剂，尤其适用于与记忆相关的功能性障碍，如包括痴呆症和精神分裂症在内的认知障碍，从而完成了本发明。